Electrocardiographic Abnormalities and Sudden Death in Myotonic Dystrophy Type 1
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sudden death can occur as a consequence of cardiac-conduction abnormalities in the neuromuscular disease myotonic dystrophy type 1. The determinants of the risk of sudden death remain imprecise. METHODS: We assessed whether the electrocardiogram (ECG) was useful in predicting sudden death in 406 adult patients with genetically confirmed myotonic dystrophy type 1. A patient was characterized as having a severe abnormality if the ECG had at least one of the following features: rhythm other than sinus, PR interval of 240 msec or more, QRS duration of 120 msec or more, or second-degree or third-degree atrioventricular block. RESULTS: Patients with severe abnormalities according to the entry ECG were older than patients without severe abnormalities, had more severe skeletal-muscle impairment, and were more likely to have heart failure, left ventricular systolic dysfunction, or atrial tachyarrhythmia. Such patients were more likely to receive a pacemaker or an implantable cardioverter-defibrillator during the follow-up period. During a mean follow-up period of 5.7 years, 81 patients died; there were 27 sudden deaths, 32 deaths from progressive neuromuscular respiratory failure, 5 nonsudden deaths from cardiac causes, and 17 deaths from other causes. Among the 17 patients who died suddenly in whom postcollapse rhythm was evaluated, a ventricular tachyarrhythmia was observed in 9. A severe ECG abnormality (relative risk, 3.30; 95% confidence interval [CI], 1.24 to 8.78) and a clinical diagnosis of atrial tachyarrhythmia (relative risk, 5.18; 95% CI, 2.28 to 11.77) were independent risk factors for sudden death. CONCLUSIONS: Patients with adult myotonic dystrophy type 1 are at high risk for arrhythmias and sudden death. A severe abnormality on the ECG and a diagnosis of an atrial tachyarrhythmia predict sudden death. (ClinicalTrials.gov number, NCT00622453.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,300
Brook, J. D., McCurrach, M. E., Harley, H. G., Buckler, A. J., Church, D., Aburatani, H., Hunter, K., Stanton, V. P., Thirion, J.-P., Hudson, T., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90154-5 · Cited by 2,777
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613
An Unstable Triplet Repeat in a Gene Related to Myotonic Muscular Dystrophy
Fu, Y. H., Pizzuti, A., Fenwick, R. G., King, J., Rajnarayan, S., Dunne, P. W., Dubel, J., Nasser, G. A., Ashizawa, T., de Jong, P., et al. (1992) · Science · doi:10.1126/science.1546326 · Cited by 1,455
Gregoratos, G., Abrams, J., Epstein, A. E., Freedman, R. A., Hayes, D. L., Hlatky, M. A., Kerber, R. E., Naccarelli, G. V., Schoenfeld, M. H., Silka, M. J., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02528-7 · Cited by 1,266
Committee Members, Gregoratos, G., Abrams, J., Epstein, A. E., Freedman, R. A., Hayes, D. L., Hlatky, M. A., Kerber, R. E., Naccarelli, G. V., Schoenfeld, M. H., et al. (2002) · Circulation · doi:10.1161/01.cir.0000035996.46455.09 · Cited by 910
Chugh, S. S., Jui, J., Gunson, K., Stecker, E. C., John, B. T., Thompson, B., Ilias, N., Vickers, C., Dogra, V., Daya, M., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.029 · Cited by 795
Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy
Buxton, J., Shelbourne, P., Davies, J., Jones, C., Tongeren, T. V., Aslanidis, C., de Jong, P., Jansen, G., Anvret, M., Riley, B., et al. (1992) · Nature · doi:10.1038/355547a0 · Cited by 620
Cloning of the essential myotonic dystrophy region and mapping of the putative defect
Aslanidis, C., Jansen, G., Amemiya, C., Shutler, G., Mahadevan, M., Tsilfidis, C., Chen, C., Alleman, J., Wormskamp, N. G. M., Vooijs, M., et al. (1992) · Nature · doi:10.1038/355548a0 · Cited by 498
A 10-year study of mortality in a cohort of patients with myotonic dystrophy
Mathieu, J., Allard, P., Potvin, L., Prévost, C., & Bégin, P. (1999) · Neurology · doi:10.1212/wnl.52.8.1658 · Cited by 414
Research works printed but not linked: 2
- Florek RC, 1990, West J Med, 153, 24
- 10.1001/jama.271.11.840 · DOI · Paper page
Cited by
Items 101–200 of 511
Hamel, J. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001184 · Cited by 48
Arrhythmias in the Muscular Dystrophies
Rajdev, A., & Groh, W. J. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.03.011 · Cited by 42
Self-citationThe myotonic dystrophy experience: a North American cross‐sectional study
Hagerman, K. A., Howe, S. J., Heatwole, C. R., & the Christopher Project Reference Group (2019) · Muscle & Nerve · doi:10.1002/mus.26420 · Cited by 42
“Because severe ECG abnormalities can predict sudden death and implantable cardioverter defibrillators may prevent some episodes of sudden death in DM, cardiac monitoring and interventions by a trained cardiologist aware of the intricacies of DM is warranted.(31,32) This study has limitations inherent to a large crosss…”
BackgroundChoudhary, P., Nandakumar, R., Greig, H., Broadhurst, P., Dean, J., Puranik, R., Celermajer, D. S., & Hillis, G. S. (2016) · Heart · doi:10.1136/heartjnl-2015-308517 · Cited by 41
Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing
Zhang, Y., Long, C., Bassel‐Duby, R., & Olson, E. N. (2018) · Physiological Reviews · doi:10.1152/physrev.00046.2017 · Cited by 45
“Clinically, patients with DM suffer muscle degeneration leading to weakness and myotonia with other symptoms including cardiac conduction defects, cataracts, brain abnormalities, as well as gastrointestinal and endocrine disorders (132, 229, 268, 330, 436).”
BackgroundRusso, R., Di Meo, F., Rago, A., Papa, A. A., Molino, A., Mosella, M., Politano, L., Russo, M. G., & Nigro, G. (2015) · PubMed · Cited by 38
Renna, L. V., Bosè, F., Iachettini, S., Fossati, B., Saraceno, L., Milani, V., Colombo, R., Meola, G., & Cardani, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184987 · Cited by 40
Thompson, R., Schoser, B. G. H., Monckton, D. G., Blonsky, K., & Lochmüller, H. (2009) · Neuromuscular Disorders · doi:10.1016/j.nmd.2009.08.009 · Cited by 37
“Eight publications have resulted from registry data, including a study showing that atrial arrhythmia and severe conduction abnormalities are risk factors for sudden death in DM1 [6].”
BackgroundHamilton, M., Robb, Y., Cumming, S. A., Gregory, H., Duncan, A., Rahman, M., McKeown, A., McWilliam, C. A., Dean, J., Wilcox, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174166 · Cited by 37
“Cardiac manifestations of DM1 include cardiomyopathy, conducting system disease and arrhythmias.[3, 4] Non-cardiac features include frontal balding, ptosis, skeletal muscle weakness, delayed muscle relaxation, diabetes and cognitive deficits.”
BackgroundInfluentialHereditary myopathies with early respiratory insufficiency in adults
Naddaf, E., & Milone, M. (2017) · Muscle & Nerve · doi:10.1002/mus.25602 · Cited by 36
Wahbi, K., Porcher, R., Laforêt, P., Fayssoil, A., Bécane, H. M., Lazarus, A., Sochala, M., Stojkovic, T., Béhin, A., Léonard-Louis, S., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4778 · Cited by 40
Recommendations for the use of electrophysiological study: Update 2018
Mureşan, L., Cismaru, G. L., Martins, R. P., Bataglia, A., Roşu, R., Puiu, M., Guşetu, G., Mada, R. O., Muresan, C., Ispas, D. R., et al. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.09.002 · Cited by 43
Russo, V., Sperlongano, S., Gallinoro, E., Rago, A., Papa, A. A., Golino, P., Politano, L., Nazarian, S., & Nigro, G. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.07.548 · Cited by 36
Increased temporal dispersion of myocardial repolarization in myotonic dystrophy Type 1
Magrì, D., Piccirillo, G., Bucci, E., Pignatelli, G., Cauti, F. M., Morino, S., Latino, P., Santini, D., Marrara, F., Volpe, M., et al. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.132 · Cited by 37
Orthopaedic Disorders in Myotonic Dystrophy Type 1: descriptive clinical study of 21 patients
Schilling, L., Forst, R., Forst, J., & Fujak, A. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-338 · Cited by 36
“The classic form (up to 1,000 repeats) starts between 10 and 30 years of age [3] with symptoms, such as distal muscle weakness, facial dysplasia, cardiac conduction defects [5,6], gastrointestinal manifestations [3], cataracts [7], cognitive changes and more rarely, skin diseases and endocrine dysfunctions [3].”
BackgroundResultQuality of life in patients with myotonic dystrophy type 2
Stojanović, V. R., Perić, S., Paunic, T., Pešović, J., Vujnić, M., Perić, M., Nikolić, A., Lavrnić, D., & Pavicevic, D. S. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.04.018 · Cited by 35
The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implications
Lallemand, B., Clémenty, N., Bernard-Brunet, A., Pierre, B., Corcia, P., Fauchier, L., Raynaud, M., Pellieux, S., & Babuty, D. (2011) · Heart · doi:10.1136/heartjnl-2011-300143 · Cited by 34
“The benefit of prophylactic pacemaker implantation was also confirmed in MD patients estimated to be at high risk of sudden death in accordance with Groh’s ECG factors.(5) 13 These previous results are a powerful argument in favour of the usefulness of electrophysiological testing in MD patients to select the candidat…”
ResultAlgalarrondo, V., Wahbi, K., Sebag, F. A., Gourdon, G., Beldjord, C., Azibi, K., Balse, E., Coulombe, A., Fischmeister, R., Eymard, B., et al. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.11.018 · Cited by 34
“Enhanced sensitivity to flecainide of transgenic DMSXL mice Since in DM1 conduction disorders are known to progress with age (Groh et al., 2008), electrocardiographic and echocardiography analysis were performed on 3-month-old and 8-monthold mice.”
BackgroundCardiac involvement in the muscular dystrophies
Silvestri, N. J., Ismail, H., ZIMETBAUM, P. J., & Raynor, E. M. (2017) · Muscle & Nerve · doi:10.1002/mus.26014 · Cited by 37
“third degree AV block was a major risk factor for SCD.(36) Patients with pacemakers also appear to be”
BackgroundInfluentialYadava, R. S., Yu, Q. C., Mandal, M., Rigo, F., Bennett, C. F., & Mahadevan, M. S. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa060 · Cited by 42
“In patients with DM1, about 30% of the deaths are due to cardiac complications (20, 21, 58).”
BackgroundCardiac Pathology in Myotonic Dystrophy Type 1
Mahadevan, M. S., Yadava, R. S., & Mandal, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111874 · Cited by 42
“This is closely followed by sudden death due to presumably cardiac causes, in about 30 to 40% of cases [27,50,51].”
BackgroundInfluentialYamashita, Y., Matsuura, T., Kurosaki, T., Amakusa, Y., Kinoshita, M., Ibi, T., Sahashi, K., & Ohno, K. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.026 · Cited by 32
van Dijk, G. P., van der Kooi, E., Béhin, A., Smeets, J. L. R. M., Timmermans, J., van der Maarel, S. M., Padberg, G. W., Voermans, N. C., & van Engelen, B. G. M. (2014) · Europe PMC (PubMed Central) · Cited by 34
Pang, P. D., Alsina, K. M., Cao, S., Koushik, A. B., Wehrens, X. H. T., & Cooper, T. A. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.010393 · Cited by 33
Distinct pathological signatures in human cellular models of myotonic dystrophy subtypes
Kim, E. Y., Barefield, D. Y., Vo, A. H., Gacita, A. M., Schuster, E. J., Wyatt, E. J., Davis, J. L., Dong, B., Sun, C., Page, P., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122686 · Cited by 38
Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1
Yin, Q., Wang, H., Li, N., Ding, Y., Xie, Z., Jin, L., Li, Y., Wang, Q., Liu, X., Xu, L., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0264-2 · Cited by 40
“Cardiac problem is considered to be a common cause of sudden death in patients with DM1 [45, 56].”
BackgroundProfound cardiac conduction delay predicts mortality in myotonic dystrophy type 1
Mörner, S., Lindqvist, P., Mellberg, C., Olofsson, B. O., Backman, C., Henein, M., Lundblad, D., & Forsberg, H. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02213.x · Cited by 32
Clinical Predictors of Conduction Disease Progression in Type I Myotonic Muscular Dystrophy
Nazarian, S., Wagner, K. R., Caffo, B. S., & Tomaselli, G. F. (2010) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2010.02905.x · Cited by 31
Chakraborty, M., Selma-Soriano, E., Magny, E. G., Couso, J. P., Pérez‐Alonso, M., Charlet‐Berguerand, N., Artero, R. D., & Llamusí, B. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.021428 · Cited by 37
“KEY WORDS: Drosophila, Heart dysfunction, Myotonic dystrophy, Muscleblind, Pentamidine”
BackgroundLong‐Term Arrhythmia Follow‐Up of Patients with Myotonic Dystrophy
Benhayon, D. A., Lugo, R. M., PATEL, R. K., Carballeira, L., Elman, L. B., & Cooper, J. M. (2014) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12604 · Cited by 30
Dynamic changes of nuclear RNA foci in proliferating DM1 cells
Xia, G., & Ashizawa, T. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1315-5 · Cited by 30
“Keywords Muscular dystrophy · Foci · Molecular marker · Neural stem cell”
BackgroundTanawuttiwat, T., Wagner, K. R., Tomaselli, G. F., & Nazarian, S. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4145 · Cited by 30
Gutiérrez‐Gutiérrez, G., Díaz‐Manera, J., Almendrote, M., Azriel, S., Bárcena, J. E., Cabezudo‐García, P., Salas, A. C., Rodríguez, C. C., Cobo, A. M., Guardiola, P. D., et al. (2019) · Neurología · doi:10.1016/j.nrl.2019.01.001 · Cited by 35
Wood, L., Bassez, G., Bleyenheuft, C., Campbell, C., Cossette, L., Jimenez‐Moreno, C., Dai, Y., Dawkins, H. J. S., Díaz‐Manera, J., Dogan, C., et al. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0889-0 · Cited by 30
Langlois, N. E. I. (2009) · Forensic Science Medicine and Pathology · doi:10.1007/s12024-009-9099-3 · Cited by 37
Postischemic cardiac recovery in heme oxygenase-1 transgenic ischemic/reperfused mouse myocardium
Juhász, B., Varga, B., Czompa, A., Bak, I., Lekli, I., Gesztelyi, R., Zsuga, J., Kemény‐Beke, Á., Antal, M., Szendrei, L., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01153.x · Cited by 32
“It is now also relatively well accepted that many human vascular diseases such as hypertension [32, 33], heart failure [34–36], organ transplantation [9, 37] and arrhythmias [38, 39] can be treated with various interventions at a level of underlying genetic mechanisms.”
BackgroundThe pivotal role of ECG in cardiomyopathies
Silvetti, E., Lanza, O., Romeo, F., Martino, A., Fedele, E., Lanzillo, C., Crescenzi, C., Fanisio, F., & Calò, L. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1178163 · Cited by 36
“A PR interval of >240 ms and QRS duration of >120 ms on ECG, as well as second- or third-degree AV block, have been demonstrated to independently predict the risk of SCD in MD1 subjects (51).”
BackgroundPriori, S. G., Blomström‐Lundqvist, C., Mazzanti, A., Blom, N. A., Borggrefe, M., Camm, A. J., Elliot, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.01.001 · Cited by 160
The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research
Wood, L., Cordts, I., Atalaia, A., Marini‐Bettolo, C., Maddison, P., Phillips, M. F., Roberts, M., Rogers, M., Hammans, S. R., Straub, V. W., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8483-2 · Cited by 28
“Pulmonary and cardiac functions are also impaired with sudden death from cardiac complications being a significant cause of fatality [3].”
BackgroundInherited neuromuscular disorders: Pathway to diagnosis
Menezes, M. P., & North, K. N. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2011.02210.x · Cited by 30
Effects of 1‐month withdrawal of ventilatory support in hypercapnic myotonic dystrophy type 1
O’Donoghue, F. J., Borel, J., Dauvilliers, Y. A., Levy, P. A., Tamisier, R., & Pépin, J. (2017) · Respirology · doi:10.1111/resp.13068 · Cited by 28
Out-of-Hospital Cardiac Arrest in Apparently Healthy, Young Adults
Tseng, Z. H., & Nakasuka, K. (2025) · JAMA · doi:10.1001/jama.2024.27916 · Cited by 34
The heart and cardiac pacing in Steinert disease.
Nigro, G., Papa, A. A., & Politano, L. (2012) · PubMed Central · Cited by 40
Cardiologic predictors of sudden death in patients with myotonic dystrophy type 1
Stojanović, V. R., Perić, S., Paunic, T., Pavlovic, S., Cvitan, E., Basta, I. Z., Perić, M., Milićev, M., & Lavrnić, D. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.09.014 · Cited by 26
“Recently, atrial tachyarrhythmia has emerged as an independent risk factor for sudden death.(7) Non-cardiac causes of sudden death, such as embolic cerebral accident and massive pulmonary embolism, have also been suggested in DM1,(13) but these have not been supported by autopsy results.”
InfluentialVentricular dysfunction in type 1 myotonic dystrophy: Electrical, mechanical, or both?
Lindqvist, P., Mörner, S., Olofsson, B. O., Backman, C., Lundblad, D., Forsberg, H., & Henein, M. Y. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.03.084 · Cited by 26
“Thirty six consecutive patients (age 45±10 years, 22 male) with DM1 from our general medicine clinic were studied who all had clinically overt myotonia and characteristic muscular dystrophy.”
BackgroundInfluentialKaminsky, P., Brembilla-Perrot, B., Pruna, L., Poussel, M., & Chenuel, B. J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.05.070 · Cited by 28
Panaite, P., Küntzer, T., Gourdon, G., Lobrinus, J. A., & Barakat, I. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010512 · Cited by 26
Arrhythmia-related workup in hereditary myopathies
Finsterer, J., Stöllberger, C., & Keller, H. (2012) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2012.02.003 · Cited by 27
Gutiérrez‐Gutiérrez, G., Díaz‐Manera, J., Almendrote, M., Azriel, S., Bárcena, J. E., Cabezudo‐García, P., Salas, A. C., Rodríguez, C. C., Cobo, A.-M., Guardiola, P. D., et al. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2019.01.008 · Cited by 31
Sommerville, R. B., Vincenti, M. G., Winborn, K., Casey, A., Stitziel, N. O., Connolly, A. M., & Mann, D. L. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.06.005 · Cited by 25
“[13] Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al.”
BackgroundInfluentialBenichou, S. A., Jauvin, D., Serres‐Bérard, T. D., Bennett, F., Rigo, F., Gourdon, G., Boutjdir, M., Chahine, M., & Puymirat, J. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.069 · Cited by 30
Guía ESC 2021 sobre estimulación cardiaca y terapia de resincronización
Glikson, M., Nielsen, J. C., Kronborg, M. B., Michowitz, Y., Auricchio, A., Barbash, I. M., Barrabés, J. A., Boriani, G., Braunschweig, F., Brignole, M., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.025 · Cited by 36
Diretriz Brasileira de Dispositivos Cardíacos Eletrônicos Implantáveis – 2023
Teixeira, R. A., Fagundes, A. A., Baggio, J. M., de Oliveira, J. C., Medeiros, P. D. T. J., Valdigem, B. P., Teno, L. A. C., Silva, R. T., de Melo, C. S., Elías, J., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20220892 · Cited by 73
Impact of Habitual Exercise on the Strength of Individuals with Myotonic Dystrophy Type 1
Brady, L., MacNeil, L., & Tarnopolsky, M. A. (2014) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000000088 · Cited by 25
“Cardiac complications as a result of conduction abnormalities, arrhythmias, and cardiomyopathies are one of the leading causes of mortality in this population, accounting for nearly a third of deaths.(9,12,33,34) As such, a full physical and cardiac assessment should be ordered for those with cardiac risk factors or t…”
BackgroundSimoncini, C., Spadoni, G., Lai, E. Y., Santoni, L., Angelini, C. I., Ricci, G., & Siciliano, G. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00624 · Cited by 28
“These features are the second life-threatening manifestation of DM1 with up to 30% of death in DM1 due to cardiac causes, of which one third are sudden cardiac death as results of conduction block or ventricular tachyarrhythmia (33, 34).”
BackgroundStoyanov, N., Winterfield, J. R., Varma, N., & Gollob, M. H. (2014) · EP Europace · doi:10.1093/europace/euu141 · Cited by 24
The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I
Koehorst, E., Ballester‐Lopez, A., Arechavala‐Gomeza, V., Martínez‐Piñeiro, A., & Nogales‐Gadea, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123939 · Cited by 27
“In addition, cardiac conduction defects are common in adult-onset DM1, which is a major contributor to increased mortality and sudden death in patients [18].”
BackgroundMyotonia Congenita and Myotonic Dystrophy: Surveillance and Management
Conravey, A., & Santana-Gould, L. (2010) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0055-z · Cited by 27
“Based on such facts, nonrandomized studies have suggested the implantation of pacemakers in DM patients with conduction abnormalities, but this intervention has not affected the rate of sudden death [ 37 ].”
BackgroundLee, K., Seah, C., Li, C. L., Chen, Y.-F., Chen, C.-Y., Wu, C.-I., Liao, P.-C., Shyu, Y., Olafson, H. R., McKee, K., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac108 · Cited by 30
Brembilla-Perrot, B., Luporsi, J. D., Léonard-Louis, S., & Kaminsky, P. (2010) · EP Europace · doi:10.1093/europace/euq423 · Cited by 23
“A low risk of sudden death was recently reported by a Canadian study.31 However, we confirm the negative impact of AF on the prognosis as reported by Groh et al.1 The follow-up of patients with type-1 MD is recommended.”
BackgroundResultInfluentialMyotonic Dystrophies and the Heart
Chaudhry, S., & Frishman, W. H. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e31821950f9 · Cited by 23
“It is believed to be both more common and severe as compared with MD2.(3)”
BackgroundRiku, Y., Watanabe, H., Mimuro, M., Iwasaki, Y., Ito, M., Katsuno, M., Sobue, G., & Yoshida, M. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8604-y · Cited by 23
Chmielewski, L., Bietenbeck, M., Patrascu, A., Rösch, S., Sechtem, U. P., Yılmaz, A., & Florian, A. R. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01414-0 · Cited by 23
Cardiac Conduction Disorders as Markers of Cardiac Events in Myotonic Dystrophy Type 1
Itoh, H., Hisamatsu, T., Tamura, T., Segawa, K., Takahashi, T., Takada, H., Kuru, S., Wada, C., Suzuki, M., Suwazono, S., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015709 · Cited by 22
Electrocardiographic predictors of infrahissian conduction disturbances in myotonic dystrophy type 1
Joosten, I. B. T., van Lohuizen, R., den Uijl, D. W., Evertz, R., de Greef, B. T. A., van Engelen, B. G. M., Faber, C. G., & Vernooy, K. (2020) · EP Europace · doi:10.1093/europace/euaa256 · Cited by 22
“Most likely, such guiding ECG criteria could significantly increase DM1 quality of care, as early PM implantation can protect against complete AV block and sudden cardiac death.(6,10) Since the 2018 ACC/AHA/HRS Guidelines also state that the recommendations for other neuromuscular disorders are similar to rec-”
BackgroundMethodInfluentialAtrial flutter in myotonic dystrophy type 1: Patient characteristics and clinical outcome
Wahbi, K., Sebag, F. A., Lellouche, N., Lazarus, A., Bécane, H. M., Bassez, G., Stojkovic, T., Fayssoil, A., Laforêt, P., Béhin, A., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.01.005 · Cited by 25
Gu, L., Wang, H., Wang, J., Guo, Y., Tang, Y., Mao, Y., Chen, L., Lou, H. J., & Ji, G. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6880 · Cited by 24
Genotype and other determinants of respiratory function in myotonic dystrophy type 1
Boussaïd, G., Wahbi, K., Laforêt, P., Eymard, B., Stojkovic, T., Béhin, A., Annane, D., Orlikowski, D., Prigent, H., & Lofaso, F. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.12.011 · Cited by 24
RNA-Binding Proteins in Heart Development
Giudice, J., & Cooper, T. A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-1221-6_11 · Cited by 26
QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance
Nazarian, S., Bluemke, D. A., Wagner, K. R., Zviman, M. M., Turkbey, E. B., Caffo, B. S., Shehata, M. L., Edwards, D., Butcher, B., Calkins, H. G., et al. (2010) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22417 · Cited by 22
Russo, V., Rago, A., & Nigro, G. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.175 · Cited by 22
Shah, A. M., Jefferies, J. L., Rossano, J. W., Decker, J. A., Cannon, B. C., & Kim, J. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.06.022 · Cited by 21
2020 Clinical practice guidelines for Bradyarrhythmias and conduction disorders
Revishvili, A. S., Artyukhina, Е. А., Глезер, М. Г., Базаев, В. А., Batalov, R. E., Bokeria, L. A., Bokeria, O. L., Davtyan, K. V., Ivanitsky, E. A., Ковалев, А. С., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4448 · Cited by 30
Pambrun, T., Mercier, A., Chatelier, A., Patri, S., Schott, J., Scouarnec, S. L., Chahine, M., Degand, B., & Bois, P. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.04.026 · Cited by 25
Maury, P., Audoubert, M., Cintas, P., Rollin, A., Duparc, A., Mondoly, P., Chiriac, A.-M., Acket, B., Zhao, X. O., Pasquié, J., et al. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.07.011 · Cited by 23
Bucci, E., Testa, M., Licchelli, L., Frattari, A., Halabieh, N. A. E., Gabriele, E., Pignatelli, G., Santis, T. D., Fionda, L., Vanoli, F., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8773-3 · Cited by 22
Souidi, A., Zmojdzian, M., & Jagla, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124104 · Cited by 23
“Bru3 stabilization also induces down-regulation of sarcomeric proteins associated with impaired motility and muscle morphology defects [59], whereas loss of MBNL1/Mbl blocks pre miR-1 processing [53] leading to up regulation of its target genes such as GJA1 and CACNA1C suggested as associated with conduction defects a…”
BackgroundBłaszczyk, E., Grieben, U. I., von Knobelsdorff‐Brenkenhoff, F., Kellman, P., Schmacht, L. M., Funk, S., Spuler, S., & Schulz‐Menger, J. (2019) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-019-0537-4 · Cited by 23
Cardona, A., Arnold, W. D., Kissel, J. T., Raman, S. V., & Zaręba, K. M. (2019) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-019-0535-6 · Cited by 23
Nikhanj, A., Yogasundaram, H., Nichols, B. M., Richman–Eisenstat, J., Phan, C. L., Bakal, J. A., Siddiqi, Z. A., & Oudit, G. Y. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014004 · Cited by 21
“The demonstrated occurrence of ventricular tachyarrhythmias in our DM1 patient cohort is consistent with the increased risk of sudden cardiac death in this patient population.(7,11,29) Of our entire MD cohort, there were 10 cardiac defibrillators (6.”
ResultMexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1
Groh, W. J., Moss, A. J., Logigian, E. L., & Moxley, R. T. (2011) · Neurology · doi:10.1212/wnl.0b013e3181fe72d7 · Cited by 23
Self-citationRole of CMR Imaging in Diagnostics and Evaluation of Cardiac Involvement in Muscle Dystrophies
Błaszczyk, E., Gröschel, J., & Schulz‐Menger, J. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00521-2 · Cited by 19
Misquitta, N. S., Ravel‐Chapuis, A., & Jasmin, B. J. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac222 · Cited by 21
Facenda-Lorenzo, M., Hernández-Afonso, J. S., Rodríguez-Esteban, M., de León-Hernández, J. C., & Grillo-Pérez, J. J. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.011 · Cited by 20
“BS en la primera visita 7 (46,7) 7 (10,6)”
BackgroundInfluentialVio, R., Zorzi, A., Bello, L., Bozzoni, V., Botta, A., Rivezzi, F., Leoni, L., Migliore, F., Bertaglia, E., Iliceto, S., et al. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.05.043 · Cited by 20
Noncoding RNAs: Emerging Players in Muscular Dystrophies
Falcone, G., Perfetti, A., Cardinali, B., & Martelli, F. (2014) · BioMed Research International · doi:10.1155/2014/503634 · Cited by 26
“For example, mexiletine, a local anesthetic and class 1B antiarrhythmic drug, reduces handgrip relaxation time in DM1 [103, 104], cardiac arrhythmia is often treated with a pacemaker or an implantable cardioverter defibrillator [105], cataracts require conventional surgery, and hypothyroidism and gonadal failure are t…”
Neuromuscular Disorders and the Role of the Clinical Electrophysiologist
Ismail, H., Raynor, E. M., & ZIMETBAUM, P. J. (2017) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2017.04.023 · Cited by 20
Clinical trials and promising preclinical applications of CRISPR/Cas gene editing
Çerçi, B., Uzay, İ. A., Kara, M. K., & Dinçer, P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121204 · Cited by 22
Anesthesia and myotonic dystrophy type 2: a case series
Weingarten, T. N., Hofer, R. E., Milone, M., & Šprung, J. (2010) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-009-9244-1 · Cited by 18
“It is well established that sudden death can occur as a consequence of cardiac-conduction abnormalities in the DM1 patients.(18) However, it is not known whether the same risk applies to DM2 patients.”
BackgroundBody composition analysis in patients with myotonic dystrophy types 1 and 2
Perić, S., Božović, I., Nišić, T., Banović, M., Vujnić, M., Švabić, T., Pešović, J., Branković, M., Basta, I. Z., Janković, M. Z., et al. (2019) · Neurological Sciences · doi:10.1007/s10072-019-03763-0 · Cited by 18
Uhm, J., Shim, J., Wi, J. H., Mun, H.-S., Park, J., Park, S., Joung, B., Pak, H., & Lee, M. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000141 · Cited by 24
Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review
Russo, V., Papa, A. A., Lioncino, M., Rago, A., Fraia, F. D., Palladino, A., Politano, L., Golino, P., & Nigro, G. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.01.002 · Cited by 22
Souidi, A., Nakamori, M., Zmojdzian, M., Jagla, T., Renaud, Y., & Jagla, K. (2023) · EMBO Reports · doi:10.15252/embr.202256616 · Cited by 16
“Cardiac repercussions including DCM are among the main causes of death in DM1 (Groh et al., 2008).”
BackgroundPediatric Neuromuscular Diseases
Rathore, G., & Kang, P. B. (2023) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2023.08.034 · Cited by 21
Valaperta, R., Gaeta, M., Cardani, R., Lombardi, F., Rampoldi, B., Siena, C. D., Mori, F., Fossati, B., Gaia, P., Ferraro, O. E., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.10.026 · Cited by 17
Chakraborty, M., Sellier, C., Ney, M., Villa, P., Charlet‐Berguerand, N., Artero, R. D., & Llamusí, B. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.032557 · Cited by 22
“The third type of cardiac dysfunction observed in DM1, although rarer, is mechanical diastolic and/or systolic dysfunction that can progress to combined systolic and diastolic heart failure (Phillips and Harper, 1997; Mathieu et al., 1999; Lazarus et al., 2002; Groh et al., 2008).”
Gutiérrez‐Gutiérrez, G., Díaz‐Manera, J., Almendrote, M., Azriel, S., Bárcena, J. E., Cabezudo‐García, P., Salas, A. C., Rodríguez, C. C., Cobo, A. M., Guardiola, P. D., et al. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.10.021 · Cited by 17
“It is known that asymptomatic patients with MD1 and electrophysiological (EP) study results showing a Hisventricular (HV) interval of ≥ 70 ms present an elevated risk of developing third-degree atrioventricular block, and benefit from prophylactic pacemaker implantation.50 However, there seem to be other causes of sud…”
BackgroundRao, A. N., Campbell, H. M., Guan, X., Word, T. A., Wehrens, X. H. T., Xia, Z., & Cooper, T. A. (2021) · JCI Insight · doi:10.1172/jci.insight.143465 · Cited by 22
“Conduction delays include prolongation of the PR interval, QRS complex and QT interval (22-24).”
Creta, A., Providencia, R. A., Gossios, T. D., Elliot, P. M., Turner, C., Savvatis, K., & Segal, O. R. (2021) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2021.01.017 · Cited by 17
Ventricular tachycardia in patients with type 1 myotonic dystrophy: a case series
Nikhanj, A., Sivakumaran, S. T., Miskew, B., Siddiqi, Z. A., & Oudit, G. Y. (2019) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytz095 · Cited by 16
“patients with DM1 as a basis for the increased risk of sudden cardiac death (SCD) in this vulnerable patient population.(5)”
Background
Metadata
- Authors
- Groh, W. J., Groh, M. R., Saha, C., Kincaid, J. C., Simmons, Z., Ciafaloni, E., Pourmand, R., Otten, R. F., Bhakta, D., Nair, G. V., Marashdeh, M. M., Zipes, D. P., & Pascuzzi, R. M.
- Affiliations
- Indiana University Indianapolis (US)
- Pennsylvania State University (US)
- University of Rochester Medicine (US)
- State University of New York (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-19
- Volume
- 358
- Issue
- 25
- Pages
- 2688-2697
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2083028245
- Cited by
- 511
- References
- 32
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 19 · 2023: 22 · 2022: 26 · 2021: 30 · 2020: 34 · 2019: 31 · 2018: 36 · 2017: 39 · 2016: 34 · 2015: 28 · 2014: 32 · 2013: 20 · 2012: 32
- FWCI
- 20.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (MO1 RR00750-27S1, M01RR000750)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Keywords
- myotonic dystrophy type 1, sudden death, electrocardiographic abnormalities, atrial tachyarrhythmia, ventricular tachyarrhythmia, cardiac conduction disorders, atrioventricular block, risk factors, implantable cardioverter-defibrillator, cardiac pacemaker, neuromuscular disorders
- MeSH terms
- Adult, Arrhythmias, Cardiac, Cause of Death, Electrocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myotonic Dystrophy, Prognosis, Risk Factors, Tachycardia, Death, Sudden, Cardiac
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.